Filtered By:
Procedure: Percutaneous Coronary Intervention
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 3177 results found since Jan 2013.
A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease
ConclusionsColchicine is an effective, relatively safe drug that could be considered for the treatment of CAD. However, we need to pay attention to the increasing occurrence of non-cardiovascular mortality and infection especially pneumonia possibly caused by colchicine.Graphical abstractEfficacy and safety of colchicine for patients with CAD.CAD coronary artery disease;RCTs randomized controlled trials;OR odds ratio;MACEs major adverse cardiovascular events;ACS acute coronary syndrome;NNT number needed to treat;NNH number needed to harm
Source: Clinical Research in Cardiology - July 28, 2023 Category: Cardiology Source Type: research
Three-year outcomes of A Randomized Multicentre Trial Comparing Revascularization and Optimal Medical Therapy for Chronic Total Coronary Occlusions (EuroCTO)
CONCLUSIONS: At 3 years there was no difference in the rate of cardiovascular death or myocardial infarction between PCI or OMT among patients with a remaining single coronary CTO. The MACE rate was higher in the OMT group due largely to ischaemia-driven revascularisation. CTO PCI appears to be a safe option for patients with a single remaining significant coronary CTO. CinicalTrials.gov: NCT01760083.PMID:37482940 | DOI:10.4244/EIJ-D-23-00312
Source: EuroIntervention - July 24, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Gerald S Werner David Hildick-Smith Victoria Martin Yuste Nicolas Boudou Georgios Sianos Valery Gelev Jose Ramon Rumoroso Andrejs Erglis Evald Hoj Christiansen Javier Escaned Carlo di Mario Luis Teruel Alexander Bufe Bernward Lauer Alfredo Ruggero Galassi Source Type: research
Acute coronary syndrome in very elderly patients —a real-world experience
AbstractVery elderly population constitutes an increasingly larger proportion of patients admitted for acute coronary syndromes (ACS). Notably, age represents both a proxy of frailty and an exclusion criterion in clinical randomized trials, which probably contributes to lack of data and undertreatment of real-world elderly patients. The aim of the study is to describe patterns of treatment and outcome of very elderly patients with ACS. All consecutive patients aged ≥ 80 years old (yo) admitted between January 2017 and December 2019 with ACS were included. The primary endpoint was in-hospital occurrence of major adv...
Source: Heart and Vessels - July 15, 2023 Category: Cardiology Source Type: research
The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
ConclusionsGenotype-guided selection of P2Y12 inhibitor made a very positive contribution on the prognosis in Chinese ACS/CCS patients undergoing PCI. Instead of intensifying antiplatelet strategies, conventional-dose clopidogrel could be recommended as P2Y12 inhibitor after weighing MACEs and bleeding events in CYP2C19 IM patients.
Source: European Journal of Clinical Pharmacology - July 14, 2023 Category: Drugs & Pharmacology Source Type: research
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
Using Artificial Intelligence in Predicting Ischemic Stroke Events After Percutaneous Coronary Intervention
CONCLUSIONS: The RF model accurately predicts short- and long-term risk of IS and outperforms logistic regression analysis in patients undergoing PCI. Patients with periprocedural stroke may benefit from aggressive management to reduce the future risk of IS.PMID:37410747
Source: The Journal of Invasive Cardiology - July 6, 2023 Category: Cardiology Authors: Chieh-Ju Chao Pradyumna Agasthi Timothy Barry Chia-Chun Chiang Panwen Wang Hasan Ashraf Farouk Mookadam Amith R Seri Nithin Venepally Mohamed Allam Sai Harika Pujari Anil Sriramoju Mohamed Sleem Said Alsidawi Mackram Eleid Nirat Beohar Floyd D Fortuin Eri Source Type: research
